 |
Video: What is a Stock Split?
|
 |
Aileron Therapeutics is a clinical stage chemoprotection oncology company. Co.'s product candidate, ALRN-6924, is a MDM2/MDMX dual inhibitor that utilizes its proprietary peptide drug technology. When used as a chemoprotective agent, ALRN-6924 is designed to activate p53, which in turn upregulates p21, an inhibitor of the cell replication cycle. ALRN-6924 is a chemoprotective agent in clinical development to employ a biomarker strategy, in which Co. focuses on treating patients with p53-mutated cancers. According to our ALRN split history records, Aileron Therapeutics has had 1 split. | |
 |

Aileron Therapeutics (ALRN) has 1 split in our ALRN split history database. The split for ALRN took place on November 11, 2022. This was a 1 for 20 reverse split, meaning for each 20 shares of ALRN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Aileron Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ALRN split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aileron Therapeutics shares, starting with a $10,000 purchase of ALRN, presented on a split-history-adjusted basis factoring in the complete ALRN split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/29/2017 |
|
End date: |
05/26/2023 |
|
Start price/share: |
$216.00 |
|
End price/share: |
$1.55 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.28% |
|
Average Annual Total Return: |
-56.63% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$71.77 |
|
Years: |
5.91 |
|
|
 |
Date |
Ratio |
11/11/2022 | 1 for 20 |
|
 |